Vitamin D regulates 175 genes (in 8 categories)
The master catalog of genes regulated by calcitriol and vitamin D receptor signaling
Cladua AI deep Research - April 2026
Calcitriol (1,25-dihydroxyvitamin D₃) directly or indirectly regulates over 200 genes through the vitamin D receptor (VDR), collectively governing calcium homeostasis, immune defense, cancer suppression, cardiovascular protection, metabolism, and brain function. This report compiles 175 VDR-regulated genes ranked by health importance, drawn from VDR ChIP-seq studies (Ramagopalan et al., Heikkinen et al., Meyer et al., Carlberg lab), transcriptomic datasets, and decades of molecular endocrinology research. The table below represents the most comprehensive available synthesis of how calcitriol's genomic actions translate into specific health benefits across virtually every organ system.
The scope of VDR's genomic reach is remarkable. ChIP-seq studies have identified 2,776 to 5,000+ VDR binding sites depending on cell type, with at least 700 genes showing direct, rapid transcriptional responses. Calcitriol simultaneously enhances antimicrobial killing while dampening autoimmune inflammation, promotes cancer cell death while protecting normal DNA, and strengthens bones while preventing vascular calcification. This report catalogs these actions gene by gene.
Eight parallel mechanisms create an integrated defense system
What makes calcitriol's gene regulatory program so medically significant is not any single gene but the coordinated, multi-pathway architecture of its actions. Eight distinct mechanistic themes emerge from this 175-gene catalog:
The antimicrobial-tolerogenic paradox is the most elegant feature. Calcitriol simultaneously upregulates pathogen-killing molecules (CAMP, DEFB4A, NOD2) while suppressing the inflammatory cytokines (TNF, IL-6, IL-17A, IFNG) and promoting tolerance mediators (FOXP3, IL-10, CTLA4). No synthetic drug achieves this dual action. The system effectively says: kill the pathogen, but do not damage the host.
The calcium transport cassette operates as a complete unit. TRPV6 opens the apical door, S100G/CALB1 shuttle calcium across the cell, and ATP2B1/SLC8A1 push it out the basolateral side. Calcitriol induces every component simultaneously, while negative feedback through CYP24A1, CYP27B1 suppression, and FGF23 induction prevents overcorrection.
The multi-layered anti-cancer program attacks malignancy from eight angles simultaneously: cell cycle arrest (p21, p27, p15 up; cyclin D1, Myc down), apoptosis promotion (BAX up, BCL-2 down), DNA repair (BRCA1, DDB2, XPC), EMT suppression (E-cadherin up, Snail down), anti-angiogenesis (VEGF down, THBS1 up), Wnt antagonism (DKK1, SFRPs), prostaglandin suppression (COX-2 down, 15-PGDH up), and detoxification (CYP3A4, SULT2A1, NRF2 cascade). This redundancy explains why single oncogene mutations cannot overcome vitamin D's protective effects.
The RAAS suppression cascade mirrors pharmaceutical interventions. Calcitriol suppresses renin (the ACE inhibitor principle), reduces angiotensin II receptors (the ARB principle), and upregulates the protective ACE2/angiotensin(1-7) arm, while enhancing eNOS for nitric oxide-mediated vasodilation — a comprehensive cardiovascular protection program.
The insulin axis is regulated end-to-end: β-cell insulin production (INS, PDX1, MAFA), insulin receptor expression (INSR), downstream signaling (IRS1, IRS2), and glucose transporter deployment (GLUT4). This makes vitamin D status a modifiable factor across the entire diabetes spectrum.
Calcium homeostasis and skeletal integrity: the foundational genes
The oldest and best-characterized VDR targets control mineral metabolism. Without these genes' regulation, rickets, osteomalacia, hypocalcemic tetany, and death would follow. Calcitriol orchestrates a complete calcium transport apparatus — apical entry channels, intracellular shuttles, and basolateral pumps — in both intestine and kidney, while simultaneously regulating phosphate balance and bone remodeling through endocrine feedback loops involving PTH, FGF23, and Klotho.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 1 | TRPV6 | Transient receptor potential vanilloid 6 | ↑ | Rate-limiting apical calcium channel in intestinal epithelium. Upregulation is essential for active dietary calcium absorption, preventing rickets in children and osteomalacia/osteoporosis in adults. Most important single gene for calcium homeostasis. |
| 2 | CYP24A1 | 24-Hydroxylase | ↑ | Most potently induced VDR target. Catabolizes calcitriol and 25(OH)D, creating the critical negative feedback loop that prevents vitamin D toxicity and lethal hypercalcemia. |
| 3 | PTH | Parathyroid hormone | ↓ | Direct suppression via negative VDRE prevents secondary hyperparathyroidism, reducing excessive bone resorption. Calcitriol analogs are standard therapy for hyperparathyroidism in chronic kidney disease. |
| 4 | CYP27B1 | 1α-Hydroxylase | ↓ | Negative feedback suppression prevents overproduction of active calcitriol, maintaining calcium-phosphate homeostasis and preventing hypercalcemia. |
| 5 | VDR | Vitamin D receptor | ↑ | Positive autoregulation amplifies tissue sensitivity to calcitriol, ensuring adequate responsiveness in intestine, bone, kidney, and immune cells. |
| 6 | CALB1 | Calbindin-D28k | ↑ | Intracellular calcium shuttle protein in kidney distal tubule and brain. Facilitates renal calcium reabsorption and provides neuroprotection by buffering intracellular calcium. |
| 7 | TRPV5 | Transient receptor potential vanilloid 5 | ↑ | Apical calcium entry channel in kidney distal tubule. Upregulation promotes renal calcium reabsorption, reducing urinary calcium loss and maintaining serum calcium. |
| 8 | S100G | Calbindin-D9k | ↑ | Intracellular calcium-buffering protein in intestinal enterocytes. Shuttles calcium across the cell during transcellular absorption, preventing toxic intracellular calcium spikes. |
| 9 | ATP2B1 | Plasma membrane Ca²⁺ ATPase (PMCA1) | ↑ | Basolateral calcium pump completing transcellular calcium transport. Extrudes calcium into blood from intestinal and renal epithelial cells. |
| 10 | SLC8A1 | Na⁺/Ca²⁺ exchanger (NCX1) | ↑ | Basolateral sodium-calcium exchanger working alongside PMCA to complete calcium extrusion into the bloodstream from absorptive cells. |
| 11 | FGF23 | Fibroblast growth factor 23 | ↑ | Stimulates this phosphaturic hormone from osteocytes, creating a bone-kidney endocrine axis that promotes renal phosphate excretion and prevents hyperphosphatemia. |
| 12 | CASR | Calcium-sensing receptor | ↑ | Enhances parathyroid gland sensitivity to serum calcium, improving PTH suppression and tightening calcium homeostatic control. |
| 13 | KL | Klotho | ↑ | Essential FGF23 co-receptor and anti-aging factor. Upregulation enhances phosphate regulation, protects against vascular calcification, and activates longevity-associated pathways. |
| 14 | SLC34A2 | NaPi-IIb (intestinal) | ↑ | Sodium-phosphate cotransporter mediating active dietary phosphate absorption, ensuring adequate phosphate for bone mineralization, ATP synthesis, and DNA. |
| 15 | CLDN2 | Claudin 2 | ↑ | Tight junction protein forming paracellular cation channels in intestine. Enhances passive calcium absorption, complementing the transcellular pathway after meals. |
| 16 | CLDN12 | Claudin 12 | ↑ | Additional tight junction protein increasing paracellular calcium permeability in the intestine, providing a secondary passive absorption route. |
| 17 | LRP2 | Megalin | ↑ | Endocytic receptor in kidney proximal tubule that reabsorbs the 25(OH)D-DBP complex from urine, conserving circulating vitamin D stores. |
| 18 | CUBN | Cubilin | ↑ | Co-receptor with megalin for renal reabsorption of vitamin D-binding protein complex, preventing urinary vitamin D loss. |
| 19 | SLC34A1 | NaPi-IIa (renal) | ↓ | Indirectly downregulated via FGF23 induction, promoting renal phosphate excretion to prevent hyperphosphatemia and ectopic calcification. |
| 20 | PHEX | Phosphate-regulating endopeptidase | ↑ | Regulates phosphate metabolism in bone; upregulation promotes proper mineralization. Loss-of-function causes X-linked hypophosphatemic rickets. |
| 21 | BGLAP | Osteocalcin | ↑ | Major non-collagenous bone protein with a well-characterized VDRE. Promotes hydroxyapatite binding and bone mineralization; also acts as an endocrine hormone improving glucose metabolism and energy homeostasis. |
| 22 | SPP1 | Osteopontin | ↑ | Multifunctional bone matrix protein directly induced via VDRE. Regulates osteoclast attachment, hydroxyapatite crystal growth, and bone remodeling; also modulates immune responses. |
| 23 | TNFSF11 | RANKL | ↑ | Essential osteoclast differentiation cytokine. Calcitriol-driven RANKL induction enables bone resorption to release skeletal calcium when needed and maintain normal bone turnover. |
| 24 | ALPL | Alkaline phosphatase | ↑ | Hydrolyzes pyrophosphate (mineralization inhibitor) to generate inorganic phosphate, promoting hydroxyapatite deposition in bone matrix. Deficiency causes hypophosphatasia. |
| 25 | RUNX2 | Runt-related transcription factor 2 | ↑ | Master transcription factor for osteoblast differentiation. Drives commitment of mesenchymal stem cells to bone-forming lineage and activates downstream bone matrix genes. |
| 26 | TNFRSF11B | Osteoprotegerin (OPG) | ↓ | Decoy receptor for RANKL. Downregulation shifts RANKL/OPG ratio to enable physiological bone resorption and remodeling. |
| 27 | IBSP | Bone sialoprotein | ↑ | Nucleates hydroxyapatite crystal formation during mineralization. Direct VDR target promoting initiation of bone mineral deposition. |
| 28 | LRP5 | LDL receptor-related protein 5 | ↑ | Wnt/β-catenin co-receptor; upregulation enhances the major anabolic bone formation pathway. Mutations cause high bone mass or osteoporosis-pseudoglioma syndrome. |
| 29 | DMP1 | Dentin matrix protein 1 | ↑ | Osteocyte protein critical for mineralization and phosphate homeostasis. Mutations cause autosomal recessive hypophosphatemic rickets. |
| 30 | MEPE | Matrix extracellular phosphoglycoprotein | ↑ | SIBLING protein regulating phosphate handling and bone mineralization through its ASARM peptide, fine-tuning mineral ion balance. |
| 31 | COL1A1 | Collagen type I alpha 1 | ↓ | At pharmacological doses, suppresses collagen synthesis to shift osteoblast activity from matrix production toward mineralization and remodeling phases. |
| 32 | SLC34A3 | NaPi-IIc (renal) | ↓ | Indirectly reduced via FGF23, promoting phosphate excretion especially during growth to prevent excessive calcium-phosphate product. |
Immune defense and inflammatory control: the dual-action network
Calcitriol's immune regulation is arguably its most medically significant non-skeletal function. The system exhibits an elegant duality: calcitriol simultaneously upregulates antimicrobial killing mechanisms while suppressing inflammatory and autoimmune pathways. This means vitamin D boosts the ability to fight infections while preventing the immune system from attacking the body's own tissues — a combination no synthetic drug has replicated.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 33 | CAMP | Cathelicidin (LL-37) | ↑ | The most celebrated VDR immune target. Direct VDRE-mediated induction in monocytes/macrophages produces LL-37, which kills M. tuberculosis, MRSA, influenza, and fungi. Also promotes wound healing. Central to the vitamin D–infection axis discovered by Liu et al. (2006, Science). |
| 34 | NFKBIA | IκBα (NF-κB inhibitor alpha) | ↑ | Master anti-inflammatory mechanism. Sequesters NF-κB in the cytoplasm, broadly suppressing transcription of TNF, IL-6, IL-1β, IL-8, adhesion molecules, and other pro-inflammatory genes across virtually all inflammatory conditions. |
| 35 | IL12B | Interleukin 12 subunit p40 | ↓ | Shared subunit of both IL-12 and IL-23. Suppression simultaneously inhibits Th1 (IL-12-driven) and Th17 (IL-23-driven) pathways — a powerful dual anti-inflammatory mechanism relevant to MS, T1D, RA, and IBD. |
| 36 | FOXP3 | Forkhead box P3 | ↑ | Master regulator of regulatory T cells (Tregs). Induction promotes immune tolerance, preventing autoimmune disease, transplant rejection, and maintaining gut homeostasis. |
| 37 | IL10 | Interleukin 10 | ↑ | Master anti-inflammatory cytokine. Upregulation suppresses Th1/Th17 effector responses, limits tissue damage during infection, and maintains mucosal immune tolerance. |
| 38 | TNF | Tumor necrosis factor | ↓ | Suppression reduces systemic inflammation, cachexia, and tissue destruction in rheumatoid arthritis, IBD, psoriasis, and sepsis. TNF is the target of the most commercially successful class of biologic drugs. |
| 39 | IL6 | Interleukin 6 | ↓ | Reduces acute-phase responses (CRP, fibrinogen), Th17 differentiation, and chronic inflammation. Lowers cardiovascular risk from chronic inflammatory states. |
| 40 | IFNG | Interferon gamma | ↓ | Shifts Th1/Th2 balance away from Th1 dominance, protecting against Th1-driven autoimmune diseases including multiple sclerosis, type 1 diabetes, and Crohn's disease. |
| 41 | IL17A | Interleukin 17A | ↓ | Suppresses Th17-driven neutrophilic inflammation and tissue damage. Relevant to psoriasis, ankylosing spondylitis, MS, and RA — diseases treated with anti-IL-17 biologics. |
| 42 | IL1B | Interleukin 1 beta | ↓ | Suppresses potent pro-inflammatory cytokine at transcriptional level and via NLRP3 inflammasome inhibition. Benefits gout, atherosclerosis, and autoinflammatory conditions. |
| 43 | NLRP3 | NLRP3 inflammasome | ↓ | Suppresses inflammasome assembly and caspase-1 activation, reducing IL-1β and IL-18 release. Protects against gout, atherosclerosis, type 2 diabetes, and Alzheimer's disease. |
| 44 | DEFB4A | Beta-defensin 2 (HBD-2) | ↑ | Broad-spectrum antimicrobial peptide induced synergistically with NOD2 signaling. Kills gram-negative bacteria and Candida at mucosal surfaces of gut, lung, and skin. |
| 45 | NOD2 | Nucleotide-binding oligomerization domain 2 | ↑ | Intracellular pattern recognition receptor sensing bacterial peptidoglycan. Creates a vitamin D–NOD2–defensin antimicrobial circuit critical for gut immunity. Mutations cause Crohn's disease. |
| 46 | HAMP | Hepcidin | ↓ | Direct VDRE-mediated suppression reduces hepcidin, increasing iron bioavailability via ferroportin. Corrects anemia of chronic disease/inflammation in CKD, IBD, and chronic infections. |
| 47 | IL23A | Interleukin 23 p19 | ↓ | Suppresses IL-23, the cytokine maintaining Th17 cell phenotype and driving chronic inflammation in psoriasis, IBD, and spondyloarthritis. |
| 48 | IL17F | Interleukin 17F | ↓ | Reduces mucosal inflammation and neutrophil recruitment, complementing IL-17A suppression in Th17-driven diseases. |
| 49 | IL12A | Interleukin 12 p35 | ↓ | Reduces IL-12p70 heterodimer, impairing Th1 polarization of naïve CD4+ T cells and dampening cell-mediated autoimmune responses. |
| 50 | TSC22D3 | GILZ (glucocorticoid-induced leucine zipper) | ↑ | Inhibits NF-κB and AP-1, suppresses pro-inflammatory cytokines, promotes tolerogenic dendritic cells. Provides glucocorticoid-like anti-inflammatory effects without metabolic side effects. |
| 51 | DUSP1 | Dual specificity phosphatase 1 (MKP-1) | ↑ | Dephosphorylates and inactivates p38 MAPK, JNK, and ERK, broadly attenuating TLR-mediated and cytokine-receptor inflammatory cascades. |
| 52 | CTLA4 | Cytotoxic T-lymphocyte associated protein 4 | ↑ | Immune checkpoint molecule on T cells. Competes with CD28 for B7 ligands, delivering inhibitory signals that maintain peripheral tolerance and prevent autoimmune tissue destruction. |
| 53 | CD274 | PD-L1 (programmed death ligand 1) | ↑ | Engages PD-1 on effector T cells to induce anergy/exhaustion, suppressing autoreactive T cell responses. Protective in autoimmunity and transplant settings. |
| 54 | IL2 | Interleukin 2 | ↓ | VDR directly interferes with NFAT/AP-1 at the IL-2 promoter, restraining clonal expansion of effector T cells while preserving Treg function. Prevents autoimmune flares. |
| 55 | SOCS1 | Suppressor of cytokine signaling 1 | ↑ | Inhibits IFN-γ/STAT1 and IL-4/STAT6 signaling, providing a critical brake on cytokine amplification loops and excessive Th1/Th2 responses. |
| 56 | SOCS3 | Suppressor of cytokine signaling 3 | ↑ | Specifically inhibits IL-6/STAT3 signaling, attenuating Th17 differentiation and IL-6-driven inflammatory responses including cytokine storm. |
| 57 | TNFAIP3 | A20 (TNF alpha induced protein 3) | ↑ | Deubiquitinating enzyme that terminates NF-κB activation downstream of TLRs, TNF-R, and IL-1R. Loss-of-function causes severe autoinflammatory disease. |
| 58 | TGFB1 | Transforming growth factor beta 1 | ↑ | Broad immunosuppressive cytokine promoting Treg differentiation (synergizes with FOXP3 induction), tissue repair, and mucosal homeostasis. |
| 59 | THBD | Thrombomodulin | ↑ | Activates protein C anticoagulant pathway, providing anti-coagulant and anti-inflammatory protection. Prevents DIC and vascular inflammation during sepsis. |
| 60 | CCL2 | MCP-1 (monocyte chemoattractant protein 1) | ↓ | Reduces monocyte/macrophage recruitment to inflammatory sites, protecting against atherosclerotic plaque formation, nephritis, and adipose tissue inflammation. |
| 61 | CXCL10 | IP-10 | ↓ | Reduces recruitment of CXCR3+ Th1/CD8+ T cells to inflammatory sites, decreasing Th1-mediated tissue damage in autoimmune thyroiditis, hepatitis, and transplant rejection. |
| 62 | DEFB103 | Beta-defensin 3 (HBD-3) | ↑ | Broad-spectrum antimicrobial active against gram-positive and gram-negative bacteria and fungi at epithelial barriers including skin and oral mucosa. |
| 63 | PI3 | Elafin (peptidase inhibitor 3) | ↑ | Dual-function molecule: antimicrobial peptide and serine protease inhibitor that protects tissues from neutrophil elastase damage during inflammation. |
| 64 | CD14 | Monocyte differentiation antigen | ↑ | Improves pathogen recognition and phagocytic capacity while concurrent TLR4 downregulation prevents excessive inflammatory signaling — balanced innate immune tuning. |
| 65 | TLR2 | Toll-like receptor 2 | ↓ | Post-activation downregulation prevents sustained pro-inflammatory signaling and hyperinflammation while antimicrobial peptide production continues via other VDR targets. |
| 66 | TLR4 | Toll-like receptor 4 | ↓ | Reduces cellular sensitivity to LPS, dampening endotoxemia, gram-negative sepsis, and chronic low-grade inflammation associated with metabolic syndrome. |
| 67 | TREM1 | Triggering receptor on myeloid cells 1 | ↓ | Attenuates the TLR amplification loop of innate inflammation, reducing risk of cytokine storm and excessive tissue damage during infections and sepsis. |
Anti-cancer mechanisms: cell cycle arrest, apoptosis, and genomic protection
Calcitriol's anti-cancer program operates through at least eight parallel mechanisms: cell cycle arrest (p21/p27/p15 induction, cyclin D1/Myc suppression), pro-apoptotic shifting (BAX up, BCL-2 down), DNA repair enhancement (BRCA1, DDB2, XPC), anti-metastatic action (E-cadherin up, Snail down), anti-angiogenesis (VEGF down, thrombospondin up), Wnt pathway antagonism (DKK1, SFRPs), prostaglandin suppression (COX-2 down, 15-PGDH up), and comprehensive detoxification (CYP3A4, SULT2A1, NRF2 cascade). This multi-layered approach explains why no single cancer gene mutation can fully overcome vitamin D's protective effects.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 68 | CDKN1A | p21 (cyclin-dependent kinase inhibitor 1A) | ↑ | The most robust anti-proliferative VDR target. Direct VDRE-mediated induction inhibits cyclin-CDK complexes, causing G1 arrest in colon, breast, prostate, and virtually all cancer types tested. |
| 69 | PTEN | Phosphatase and tensin homolog | ↑ | Tumor suppressor that antagonizes PI3K/Akt survival signaling. Upregulation suppresses oncogenic cell survival, proliferation, and metabolic reprogramming in prostate and breast cancers. |
| 70 | MYC | c-Myc proto-oncogene | ↓ | Suppression of this master proliferation regulator reduces expression of cell cycle genes, ribosome biogenesis, and metabolic reprogramming. Key mechanism in colon cancer, leukemia, and breast cancer. |
| 71 | BAX | BCL2-associated X protein | ↑ | Shifts BAX/BCL-2 ratio toward apoptosis. BAX forms mitochondrial pores releasing cytochrome c, activating caspase cascades to eliminate damaged/transformed cells. |
| 72 | BCL2 | B-cell lymphoma 2 | ↓ | Removes the key anti-apoptotic brake on mitochondrial membrane permeabilization. Combined with BAX upregulation, sensitizes cancer cells to programmed cell death. |
| 73 | BRCA1 | Breast cancer 1 | ↑ | Induced via functional VDRE in its promoter. Essential for homologous recombination DNA repair. The vitamin D–BRCA1 axis is particularly relevant to breast and ovarian cancer prevention. |
| 74 | CCND1 | Cyclin D1 | ↓ | Reduces this essential G1 cyclin both transcriptionally and post-translationally. Cooperates with p21/p27 upregulation to enforce G0/G1 arrest. Overexpressed in breast, colon, and many cancers. |
| 75 | IGFBP3 | Insulin-like growth factor binding protein 3 | ↑ | Sequesters IGF-1/IGF-2, blocking PI3K/Akt and MAPK survival signaling. Also has IGF-independent pro-apoptotic effects in prostate and breast cancers. |
| 76 | CDH1 | E-cadherin | ↑ | Preserves epithelial cell-cell adhesion and blocks epithelial-to-mesenchymal transition (EMT). E-cadherin loss is a hallmark of invasion and metastasis in colon, breast, and other carcinomas. |
| 77 | GADD45A | Growth arrest and DNA damage inducible alpha | ↑ | Dual function: promotes G2/M cell cycle arrest and participates in DNA repair via PCNA interaction. Provides a critical checkpoint against genomic instability. |
| 78 | CDKN1B | p27 (cyclin-dependent kinase inhibitor 1B) | ↑ | Stabilized by calcitriol (reduced proteasomal degradation via SKP2 downregulation). Inhibits cyclin E–CDK2, reinforcing G1 arrest in prostate, breast, and colon cancers. |
| 79 | DDB2 | Damage-specific DNA binding protein 2 | ↑ | Key nucleotide excision repair (NER) component recognizing UV-induced DNA damage. Upregulation enhances DNA repair, providing photoprotection and reducing skin cancer risk. |
| 80 | XPC | Xeroderma pigmentosum group C | ↑ | Primary sensor of helix-distorting DNA lesions in global genome NER. Works with DDB2 to accelerate removal of DNA damage, reducing mutagenesis and cancer initiation. |
| 81 | PTGS2 | COX-2 (prostaglandin-endoperoxide synthase 2) | ↓ | Suppresses inducible PGE2 synthesis. PGE2 promotes tumor proliferation, angiogenesis, and immune evasion. COX-2 suppression mirrors the chemopreventive effects of NSAIDs, especially in colorectal cancer. |
| 82 | HPGD | 15-PGDH (15-hydroxyprostaglandin dehydrogenase) | ↑ | Catabolizes and inactivates PGE2. Combined with COX-2 suppression, creates a two-pronged reduction in pro-tumorigenic prostaglandin levels — a key colorectal cancer prevention mechanism. |
| 83 | SNAI1/SNAI2 | Snail/Slug | ↓ | Represses master EMT transcription factors that would otherwise suppress E-cadherin and promote mesenchymal gene expression, preventing cancer cell invasion and metastatic dissemination. |
| 84 | VEGFA | Vascular endothelial growth factor A | ↓ | Suppresses the major pro-angiogenic signal in tumor cells, restricting blood vessel formation needed for tumor growth beyond 1-2 mm. Demonstrated in prostate, breast, and colon cancer. |
| 85 | THBS1 | Thrombospondin 1 | ↑ | Potent endogenous angiogenesis inhibitor. Activates TGF-β and induces endothelial cell apoptosis via CD36, cutting off tumor blood supply. |
| 86 | DKK1 | Dickkopf-1 | ↑ | Secreted Wnt antagonist binding LRP5/6. Blocks aberrant Wnt/β-catenin signaling — the most frequently mutated oncogenic pathway in colorectal cancer — reducing nuclear β-catenin and its target genes c-Myc and cyclin D1. |
| 87 | SFRP1 | Secreted frizzled-related protein 1 | ↑ | Decoy receptor sequestering Wnt ligands from Frizzled receptors. Frequently silenced by methylation in cancers; vitamin D-mediated restoration suppresses Wnt-driven proliferation. |
| 88 | SFRP2 | Secreted frizzled-related protein 2 | ↑ | Additional Wnt antagonist providing redundant suppression of aberrant Wnt signaling. Particularly protective in colorectal cancer. |
| 89 | KLF4 | Kruppel-like factor 4 | ↑ | Promotes cellular differentiation, induces p21, and suppresses oncogenic pathways. Acts as tumor suppressor driving differentiation toward mature, non-proliferative phenotype in colorectal cancer. |
| 90 | CST5 | Cystatin D | ↑ | Cysteine protease inhibitor suppressing cathepsin-mediated matrix degradation and invasion. Direct VDR target with tumor suppressor properties in colon cancer; also inhibits Wnt signaling. |
| 91 | BCL2L11 | BIM (BH3-only protein) | ↑ | Potent pro-apoptotic protein that neutralizes anti-apoptotic BCL-2 family members and directly activates BAX/BAK. Enhances apoptotic response in SCC and breast cancer. |
| 92 | CDKN2B | p15 (cyclin-dependent kinase inhibitor 2B) | ↑ | Specifically inhibits CDK4/CDK6, blocking Rb phosphorylation and G1-to-S transition. Demonstrated in myeloid leukemia where vitamin D promotes differentiation. |
| 93 | RB1 | Retinoblastoma protein | ↑ | Maintained in active hypophosphorylated state by CDK inhibitor upregulation and cyclin downregulation, sequestering E2F to block S-phase entry. |
| 94 | E2F1 | E2F transcription factor 1 | ↓ | Functionally repressed via Rb sequestration, preventing expression of DNA synthesis genes (thymidylate synthase, DNA polymerase α, DHFR). |
Cardiovascular protection through RAAS suppression and endothelial health
Calcitriol's cardiovascular benefits center on suppression of the renin-angiotensin-aldosterone system (RAAS) — the same pathway targeted by ACE inhibitors and ARBs, two of the most prescribed drug classes worldwide. VDR-null mice develop cardiac hypertrophy and hypertension, confirming the physiological importance of these genomic actions.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 95 | REN | Renin | ↓ | Directly suppressed via negative VDRE (Li et al., 2002). Reduces RAAS activation, lowering blood pressure and decreasing cardiac and renal fibrosis. VDR-null mice show markedly elevated renin. |
| 96 | NOS3 | Endothelial nitric oxide synthase (eNOS) | ↑ | Increases NO bioavailability in endothelial cells, promoting vasodilation, improving endothelial function, and reducing platelet aggregation and leukocyte adhesion. |
| 97 | ACE2 | Angiotensin-converting enzyme 2 | ↑ | Converts angiotensin II to vasodilatory angiotensin(1-7), shifting RAAS balance toward cardioprotection. Also relevant to COVID-19 pathophysiology. |
| 98 | AGTR1 | Angiotensin II receptor type 1 | ↓ | Reduces AT1R-mediated vasoconstriction, aldosterone secretion, vascular inflammation, and fibrosis. |
| 99 | ACE | Angiotensin-converting enzyme | ↓ | Reduces angiotensin II production, decreasing vasoconstriction, oxidative stress, and inflammatory signaling. |
| 100 | EDN1 | Endothelin-1 | ↓ | Suppresses potent vasoconstrictor in endothelial and vascular smooth muscle cells, reducing cardiac remodeling and vascular inflammation. |
| 101 | MMP9 | Matrix metalloproteinase 9 | ↓ | Suppresses matrix degradation in macrophages and vascular smooth muscle, reducing atherosclerotic plaque instability, aortic aneurysm risk, and pathological vascular remodeling. |
| 102 | AGT | Angiotensinogen | ↓ | Reduces substrate availability for angiotensin II production, further dampening RAAS activation. |
| 103 | NPPA | Natriuretic peptide A (ANP) | ↓ | Normalization reflects reduced cardiac wall stress and improved cardiac function. |
| 104 | NPPB | Natriuretic peptide B (BNP) | ↓ | Reduction indicates alleviated cardiac volume/pressure overload and improved heart failure status. |
| 105 | SERPINE1 | PAI-1 (plasminogen activator inhibitor 1) | ↓ | Reduces thrombotic risk by decreasing the primary inhibitor of fibrinolysis. Protective against venous thromboembolism and atherothrombosis. |
Metabolic regulation: insulin secretion, sensitivity, and glucose control
Calcitriol regulates the entire insulin signaling axis — from pancreatic β-cell insulin production to peripheral tissue insulin sensitivity — making vitamin D deficiency a modifiable risk factor for both type 1 and type 2 diabetes.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 106 | INS | Insulin | ↑ | Enhances insulin gene transcription in β-cells via a VDRE in the INS promoter (Maestro et al., 2003). Improves glucose-stimulated insulin secretion and glycemic control. |
| 107 | INSR | Insulin receptor | ↑ | Increases insulin receptor expression (Maestro et al., 2000), enhancing cellular insulin sensitivity and glucose uptake in target tissues. |
| 108 | PDX1 | Pancreatic and duodenal homeobox 1 | ↑ | Master β-cell transcription factor. Promotes β-cell development, survival, and insulin transcription. |
| 109 | MAFA | MAF bZIP transcription factor A | ↑ | Critical transcription factor for glucose-stimulated insulin secretion in mature β-cells. Enhances the coupling of glucose sensing to insulin release. |
| 110 | SLC2A4 | GLUT4 (glucose transporter type 4) | ↑ | Increases insulin-stimulated glucose uptake in skeletal muscle and adipose tissue, directly improving glucose disposal. |
| 111 | IRS1 | Insulin receptor substrate 1 | ↑ | Enhances downstream insulin signaling cascade, improving glucose metabolism and insulin sensitivity. |
| 112 | IRS2 | Insulin receptor substrate 2 | ↑ | Critical for β-cell survival and hepatic insulin signaling. Enhances β-cell mass and function. |
| 113 | ADIPOQ | Adiponectin | ↑ | Insulin-sensitizing, anti-inflammatory, and anti-atherogenic adipokine. Enhances fatty acid oxidation and improves metabolic syndrome. |
| 114 | PPARG | PPARγ | ↑ | Promotes insulin sensitization and healthy adipocyte differentiation, improving lipid metabolism and reducing insulin resistance. |
| 115 | LEP | Leptin | ↓ | Reduces hyperleptinemia and leptin resistance, improving appetite regulation and metabolic homeostasis. |
| 116 | PCK1 | Phosphoenolpyruvate carboxykinase 1 | ↓ | Reduces hepatic gluconeogenesis, lowering fasting glucose in type 2 diabetes and insulin resistance. |
| 117 | CYP7A1 | Cholesterol 7α-hydroxylase | ↓ | Modulates bile acid synthesis and cholesterol metabolism. Suppression via VDR-SHP axis regulates enterohepatic circulation. |
| 118 | NR0B2 | SHP (small heterodimer partner) | ↑ | Transcriptional repressor of bile acid synthesis genes. Protects against bile acid toxicity and modulates lipid/cholesterol metabolism. |
| 119 | HMGCR | HMG-CoA reductase | ↓ | Rate-limiting enzyme in cholesterol synthesis. Downregulation reduces endogenous cholesterol production — the same target as statin drugs. |
Neuroprotection: neurotrophins, neurotransmitters, and anti-Alzheimer's actions
VDR is expressed throughout the brain, and calcitriol regulates a remarkable constellation of neurological genes spanning neurotrophic factor production, neurotransmitter synthesis, and amyloid clearance. The TPH2 regulation is particularly notable — Patrick and Ames (2014) identified a VDRE in the TPH2 promoter, directly linking vitamin D to brain serotonin production and mental health.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 120 | TPH2 | Tryptophan hydroxylase 2 | ↑ | Rate-limiting enzyme for brain serotonin synthesis. Direct VDRE-mediated activation (Patrick & Ames, 2014, FASEB J). Increases brain serotonin, improving mood, social behavior, and executive function. Relevant to depression, anxiety, autism, and seasonal affective disorder. |
| 121 | NGF | Nerve growth factor | ↑ | Promotes survival of cholinergic neurons, synaptic plasticity, and cognitive maintenance. Protects against Alzheimer's-related cholinergic degeneration. |
| 122 | GDNF | Glial cell-derived neurotrophic factor | ↑ | Promotes survival and maintenance of dopaminergic neurons. Neuroprotective in Parkinson's disease models. |
| 123 | BDNF | Brain-derived neurotrophic factor | ↑ | Enhances synaptic plasticity, learning, memory, and adult neurogenesis. Deficiency linked to depression, Alzheimer's, and cognitive decline. |
| 124 | TH | Tyrosine hydroxylase | ↑ | Rate-limiting enzyme for dopamine synthesis. Enhances dopaminergic neurotransmission, supporting motor function, motivation, and reward circuits. Relevant to Parkinson's disease. |
| 125 | CHAT | Choline acetyltransferase | ↑ | Increases acetylcholine synthesis, supporting memory, learning, and cognitive function. Addresses the cholinergic deficit central to Alzheimer's pathology. |
| 126 | APP | Amyloid precursor protein | ↓ | Reduces APP expression and amyloid-β production, decreasing amyloid plaque burden — the pathological hallmark of Alzheimer's disease. |
| 127 | BACE1 | Beta-secretase 1 | ↓ | Suppresses the enzyme that cleaves APP to generate amyloid-β42. Reduces Aβ generation, potentially slowing Alzheimer's disease progression. |
| 128 | GAD1 | Glutamate decarboxylase 1 | ↑ | Enhances GABAergic inhibitory neurotransmission, critical for neuronal circuit balance. Relevant to epilepsy, schizophrenia, and autism. |
| 129 | NTF3 | Neurotrophin 3 | ↑ | Supports survival and differentiation of developing neurons, particularly proprioceptive and sensory neurons. |
| 130 | SLC6A4 | Serotonin transporter (SERT) | ↓ | Reduces serotonin reuptake, increasing synaptic serotonin availability — the same mechanism as SSRI antidepressants. |
| 131 | VGF | VGF nerve growth factor inducible | ↑ | Neuropeptide precursor promoting synaptic plasticity, energy homeostasis, and neuroprotection. Reduced in Alzheimer's, depression, and Huntington's disease. |
| 132 | NOS1 | Neuronal nitric oxide synthase | ↓ | Limits excessive NO/peroxynitrite production in pathological conditions, reducing oxidative neuronal damage in stroke, TBI, and neurodegeneration. |
Detoxification, antioxidant defense, and cytoprotective cascades
Calcitriol activates all three phases of xenobiotic metabolism and the master antioxidant response, creating a comprehensive cellular defense system against environmental carcinogens, oxidative stress, and metabolic toxins.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 133 | NFE2L2 | NRF2 (nuclear factor erythroid 2-related factor 2) | ↑ | Master transcription factor of the antioxidant response. Drives expression of glutathione S-transferases, NAD(P)H quinone oxidoreductase, and detoxification enzymes. Amplifies entire cellular antioxidant defense. |
| 134 | CYP3A4 | Cytochrome P450 3A4 | ↑ | Major phase I enzyme metabolizing dietary carcinogens and xenobiotics in intestine and liver. Contains functional VDREs. Enhances first-pass carcinogen clearance, especially relevant to colon cancer prevention. |
| 135 | SOD2 | Superoxide dismutase 2 (MnSOD) | ↑ | Mitochondrial antioxidant converting superoxide to hydrogen peroxide. Protects mitochondrial DNA and prevents oxidative damage driving genomic instability and cancer. |
| 136 | GPX1 | Glutathione peroxidase 1 | ↑ | Selenoenzyme reducing hydrogen peroxide and lipid hydroperoxides. Reduces oxidative DNA damage, lipid peroxidation, and protein oxidation across all tissues. |
| 137 | HMOX1 | Heme oxygenase 1 | ↑ | Degrades pro-oxidant free heme into antioxidant biliverdin, anti-inflammatory CO, and iron (sequestered by ferritin). Especially protective in colon where dietary heme is a cancer risk factor. |
| 138 | CAT | Catalase | ↑ | Decomposes hydrogen peroxide into water and oxygen. Works with SOD2 and GPX1 to maintain redox balance and prevent oxidative mutagenesis. |
| 139 | TXNRD1 | Thioredoxin reductase 1 | ↑ | Maintains the thioredoxin system in reduced state, critical for redox regulation, DNA synthesis support, and oxidative stress defense. |
| 140 | SULT2A1 | Sulfotransferase 2A1 | ↑ | Phase II conjugation enzyme sulfonating bile acids and xenobiotics for elimination. Reduces exposure to tumor-promoting bile acid metabolites, especially in colorectal cancer prevention. |
| 141 | ABCB1 | P-glycoprotein (MDR1) | ↑ | Phase III efflux transporter pumping xenobiotics and carcinogens out of cells. Contains VDREs. Reduces intracellular genotoxic compound accumulation. |
| 142 | ABCC2 | MRP2 (multidrug resistance protein 2) | ↑ | Additional phase III efflux transporter in intestine and liver enhancing elimination of conjugated toxins and carcinogens. |
| 143 | ABCG2 | BCRP (breast cancer resistance protein) | ↑ | Efflux transporter protecting stem cells and epithelial barriers from xenobiotic accumulation. |
| 144 | CYP2B6 | Cytochrome P450 2B6 | ↑ | Phase I enzyme contributing to detoxification of drugs and environmental chemicals in liver. |
Skin barrier, muscle function, and tissue-specific protective genes
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 145 | FLG | Filaggrin | ↑ | Essential for skin barrier integrity and natural moisturizing factor production. Deficiency causes atopic dermatitis and allergic sensitization. |
| 146 | IVL | Involucrin | ↑ | Structural component of the cornified cell envelope, strengthening the skin's physical barrier against pathogens and allergens. |
| 147 | LOR | Loricrin | ↑ | Major cornified envelope protein. Upregulation improves epidermal barrier strength and integrity. |
| 148 | TGM1 | Transglutaminase 1 | ↑ | Crosslinks cornified envelope proteins (involucrin, loricrin), creating the covalent bonds that make the skin barrier mechanically robust. |
| 149 | KRT1 | Keratin 1 | ↑ | Supports proper suprabasal keratinocyte differentiation and epidermal stratification. |
| 150 | KRT10 | Keratin 10 | ↑ | Suprabasal keratin essential for normal epidermal differentiation and barrier formation. |
| 151 | MSTN | Myostatin | ↓ | Negative regulator of muscle growth. Suppression promotes muscle hypertrophy, strength, and regeneration. Critical for preventing sarcopenia, cancer cachexia, and age-related muscle wasting. |
| 152 | MYOD1 | Myogenic differentiation 1 | ↑ | Master transcription factor for skeletal muscle differentiation. Drives muscle repair and regeneration. |
| 153 | IGF1 | Insulin-like growth factor 1 | ↑ | Promotes muscle protein synthesis, satellite cell proliferation, and muscle regeneration. |
| 154 | FOXO1 | Forkhead box O1 | ↓ | Nuclear activity suppression prevents muscle protein degradation and atrophy by inhibiting atrogin-1/MuRF1 programs. |
| 155 | OCLN | Occludin | ↑ | Tight junction protein maintaining epithelial barrier integrity in gut and other mucosal surfaces. Protects against "leaky gut" and pathogen translocation. |
| 156 | TJP1 | ZO-1 (tight junction protein 1) | ↑ | Scaffolding protein anchoring tight junctions to the cytoskeleton. Strengthens epithelial barriers in intestine and other epithelia. |
| 157 | SLC40A1 | Ferroportin | ↑ | The sole cellular iron exporter. Upregulated as a consequence of hepcidin suppression, increasing iron release from enterocytes and macrophages to correct anemia. |
| 158 | AQP2 | Aquaporin 2 | ↑ | Renal collecting duct water channel. Upregulation supports proper water reabsorption and urine concentration. |
| 159 | HR | Hairless | ↑ | Classical VDR target essential for hair follicle cycling. VDR mutations that disrupt HR interaction cause alopecia, demonstrating VDR-HR cooperation in hair biology. |
Autophagy, epigenetics, and longevity-associated genes
Emerging research reveals calcitriol's regulation of cellular quality control and aging pathways, including autophagy for clearing damaged organelles, epigenetic modifiers controlling gene accessibility, and telomere maintenance enzymes. The SIRT1–FOXO3–TERT axis represents a longevity network directly enhanced by vitamin D signaling.
| Rank | Gene | Full Name | ↑/↓ | How calcitriol regulation improves health |
|---|---|---|---|---|
| 160 | BECN1 | Beclin 1 | ↑ | Key initiator of autophagosome formation (Yuk et al., 2009). Enhances autophagy for clearance of damaged organelles, misfolded proteins, and intracellular pathogens including M. tuberculosis. |
| 161 | ATG5 | Autophagy related 5 | ↑ | Essential for autophagosome elongation and maturation. Improved autophagic flux clears damaged cellular components and intracellular bacteria. |
| 162 | ATG16L1 | Autophagy related 16 like 1 | ↑ | Critical for intestinal epithelial defense and Paneth cell function. Variants are Crohn's disease risk factors; upregulation supports gut immune homeostasis. |
| 163 | SIRT1 | Sirtuin 1 | ↑ | Master longevity regulator. NAD⁺-dependent deacetylase promoting DNA repair, mitochondrial biogenesis, and anti-inflammatory responses via FOXO3, p53, PGC-1α, and NF-κB deacetylation. |
| 164 | FOXO3 | Forkhead box O3 | ↑ | Longevity gene identified in GWAS. Induces SOD2, catalase, and autophagy genes. Promotes DNA repair and oxidative stress resistance. |
| 165 | TERT | Telomerase reverse transcriptase | ↑ | Maintains telomere length in normal and immune cells, delaying cellular senescence. Context-dependent: downregulated in cancer cells to limit proliferation. |
| 166 | PPARGC1A | PGC-1α | ↑ | Master regulator of mitochondrial biogenesis. Enhances oxidative phosphorylation capacity, energy production, and metabolic fitness. |
| 167 | TFAM | Mitochondrial transcription factor A | ↑ | Drives mitochondrial DNA transcription and replication. Supports mitochondrial mass and function, protecting against age-related mitochondrial decline. |
| 168 | NRF1 | Nuclear respiratory factor 1 | ↑ | Transcription factor coordinating nuclear-encoded mitochondrial gene expression with mitochondrial biogenesis. |
| 169 | KDM6B | JMJD3 (histone H3K27 demethylase) | ↑ | Removes repressive H3K27me3 marks, enabling transcription of calcitriol target genes. Epigenetic gatekeeper of VDR-mediated gene activation in immune cells. |
| 170 | TET2 | Tet methylcytosine dioxygenase 2 | ↑ | DNA demethylase converting 5-methylcytosine to 5-hydroxymethylcytosine. Promotes active DNA demethylation and gene reactivation, relevant to tumor suppressor gene re-expression. |
| 171 | DNMT1 | DNA methyltransferase 1 | ↓ | Reduces maintenance DNA methylation, potentially enabling re-expression of silenced tumor suppressor genes in cancer. |
| 172 | EZH2 | Enhancer of zeste homolog 2 | ↓ | Polycomb component catalyzing repressive H3K27me3 marks. Downregulation reduces epigenetic silencing of tumor suppressors. Overexpressed in aggressive cancers. |
| 173 | PER2 | Period circadian regulator 2 | ↑ | Core clock gene. Upregulation supports circadian rhythm integrity, which governs immune function, metabolism, DNA repair timing, and cancer susceptibility. |
| 174 | BMAL1 | Brain and muscle ARNT-like 1 | ↑ | Master circadian transcription factor. Proper regulation supports metabolic rhythms, immune cycling, and sleep-wake homeostasis. |
| 175 | ALOX15 | Arachidonate 15-lipoxygenase | ↑ | Generates specialized pro-resolving mediators (lipoxins, resolvins) from arachidonic acid. Promotes active resolution of inflammation rather than just suppression. |
Conclusion
This catalog of 175 calcitriol-regulated genes reveals vitamin D not as a single-function nutrient but as a master genomic regulator operating through the VDR across virtually every organ system. The three most impactful regulatory domains are calcium/skeletal homeostasis (preventing rickets, osteoporosis, and hypocalcemic death), immune dual-regulation (enhancing antimicrobial defense while suppressing autoimmunity), and multi-pathway cancer suppression (attacking malignancy through at least eight independent mechanisms).
Several practical insights emerge. First, the sheer number of simultaneously regulated genes explains why observational studies consistently find vitamin D deficiency associated with diverse diseases — it is not confounding but biology. Second, the tissue-specific nature of VDR binding (2,776 sites in lymphoblastoid cells vs. 5,000+ in prostate cells) means calcitriol's gene targets vary by organ, explaining tissue-specific disease associations. Third, many of these genes show dose-response relationships, with physiological versus pharmacological calcitriol concentrations sometimes producing different effects — a critical consideration for supplementation strategy. Finally, the emerging categories of autophagy, epigenetic, circadian, and mitochondrial gene regulation suggest that vitamin D's full genomic impact is still being discovered, with new VDR targets identified in every major ChIP-seq study published.
Related in Vitamin D Life
- 10,000 years of gene changes: increasing many health problems, 2 Vitamin D changes,
- Alzheimer’s is associated with all 7 of the genes which restrict vitamin D from getting to tissues
- Genes and Vitamin D – literature review
- Benefits of Vitamin D often limited by genes
How many genes?
- Vitamin D up and down regulates 1,000’s of genes via the Vitamin D Receptor
- 179 immune system genes changed activation after Vitamin D added to blood in test tube - Carlberg
- Vitamin D effects on over 300 genes varies with genetics and levels
- 1289 genes changed with higher doses of Vitamin D - RCT
- 229 Genes related to vitamin D